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Abstract
It has been reported that the water extract of the whole unripe fruit of Momordica charantia can significantly 
reduce blood glucose levels. However the safety of its use during pregnancy has not been fully investigated. The aim 
of this investigation is to determine the safety of this extract during pregnancy. The water extract of the unripe fruit 
was given to pregnant Sprague Dawley rats on days 7, 8, 9, 10, 11, 12, 13 and 14 of gestation. The litter size was 
determined for each group and the litters were examined for gross malformations. The gross and histological 
examinations of various organs of the litters were also carried out. Results show that 8.65% of the litters from 
experimental animals were malformed as against 1.62% of control. It also showed that 31.2% of all the malformed 
litters had multiple congenital malformations. It also showed that the experimental rats had nine resorption sites 
while control had none. This demonstrates that the water extract of Momordica charantia is teratogenic in Sprague 
Dawley rats and should be used with caution in man.
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Introduction
The placenta provides a selective barrier between the fetus and the mother. This barrier protects the fetus 
from some harmful substances crossing from the mother to the fetus. Chemicals (including drugs) are among some 
harmful agents that sometimes breach this barrier.
Since teratogenicity of thalidomide was highlighted a lot of research has been undertaken to determine the 
safety of different drugs during pregnancy. To emphasize the importance of this, most drug manufacturers always 
include the caution “not to be used in pregnancy unless prescribed by a physician”, in their directions for use of 
drugs.
Herbal preparations have been in use before the onset of pharmaceutical products. However, their use has
been dramatically increased recently; hence such terms as “herbal medicine and alternative medicine” are gradually 
finding their way into medicinal curricula. The use of herbs for the management of different illnesses is appealing 
because it is cheap and readily available. It also reduces the stress of the hospital environment. Herbalists have been 
practising their trade for ages. This is usually done with some degree of secrecy. Furthermore, the complications that 
might be associated with their use are not usually highlighted.
Extracts from different parts of Momordica charantia have been reported to have medicinal values. 
Different extracts have been reported used for the treatment of infections ( Chen et al., 2009, Sonibare et al., 2009), 
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hyperglycemia ( Uche-Nwachi and Mitchell, 2004; Han et al., 2008; Shih et al., 2009; Gbolade, 2009) and wound 
healing (Teoh et al., 2009; Alam et al., 2009; Lii et al., 2009; Ono et al., 2009). 
One of the commonest uses is in the control of blood glucose in diabetics. The mode of action in the 
hypoglycemic property of Momordica charantia, has been extensively studied with varying results. Krawinkel and 
Keding (2006), reported that, the mechanism of action, whether it is via  regulation of insulin release or altered 
glucose metabolism and its insulin-like effect is still under debate while Shih et al. (2009), reported that Momordica 
charantia extract acts by decreasing insulin resistance and increases glucose transporter protein 4 (GLUT4) in 
skeletal muscles. Herbalists usually administer the water extracts to diabetics to control their blood glucose.
The incidence of diabetes has been on the increase. Many diabetic patients in rural communities use herbal 
hypoglycemic agents for the control of their blood sugar. One of the herbs most frequently used is coralli/bitter gourd
(Momordica charantia). Momordica charantia has been native to the tropics. According to Seaforth (1998), the herb 
is found in some parts of the Amazon, East Africa, Asia, and the Caribbean and has been used as a folklore medicine 
to treat various ailments including diabetes. Several investigators including Welinhinda et al. (1986), Ahmed et al.
(1998), Ahmad et al, (1999), Sitasawad et al (2000), Lin et al. (2001), Miura et al. (2001), Vikrant et al (2001), 
Biyani et al, (2003) and Uche-Nwachi and Mitchell (2004), Gbolade et al (2009), Shih et al (2009), Han et al (2008),
also had reported that the hypoglycemic property of the aqueous extract of Momordica charantia. Singh et al. (1989), 
Day et al (1990), Higashino et al (1992), and Ali et al (1993) had reported that extracts of the entire unripe fruit have
been used as a hypoglycemic agents.  However, other investigators, including Chongkol et al (1987), Karuanayake et 
al, (1990), Cakici et al (1994), and Platel and Sirnivasan (1995), reported that the hypoglycemic property of 
Momordica charantia depended on what part of the fruit used and the method of extraction employed. Uche-Nwachi 
and Mitchell (2004) reported that, while the unripe whole fruit extract had comparable hypoglycemic property to 
insulin and oral hypoglycemic drugs, that the ripe fruit did not possess this property. They also found that the extract 
lost its hypoglycemic property if not refrigerate. In spite of findings of these investigators, not much has been done to
determine the safety of the use of Momordica charantia extracts in pregnancy.  The aim of this investigation is to 
determine its possible teratogenic effect and its safety in pregnancy.
Materials and Methods
Animals
Fifty three Sprague Dawley female rats weighing 280-380 grams were selected from the Animal House in
the Faculty of Medical Sciences, University of the West Indies. The animals were acclimatized for two weeks, under 
standard conditions of temperature and illumination (12 hr light and 12 hrs dark) cycle. Animals had access to food 
(standard rat diet) and water ad libitum, and were cared for according to the Animal House Committee regulations on 
“the Care of Experimental Animals”.
Confirmation of pregnancy
Vaginal smears were taken every two hours during the day, to determine the estrus cycle based upon 
vaginal cytology. Rats with proestrus vaginal cytology were grouped in threes. Each group was placed in a cage with 
a virile male for mating. Mating was confirmed by the presence of spermatozoa in the vaginal smear. This was the 
sperm positive date and corresponds to day zero in the dating of the animals. The pregnant rats were weighed daily. 
A significant weight gain on the 10th day of gestation was also confirmatory of pregnancy.
Preparation of Extracts
Unripe Momordica charantia was obtained from the local market. The water extract was prepared using 
5kg of the whole unripe fruit including the seeds and 300ml of distilled water. This was blended using a commercial 
blender until pulp was formed. This was then strained using a cheese cloth to remove the coarse fibers. 
Treatment
The experimental animals were divided into groups of three. A total of 8 groups (1-8) were acclimatized in 
separate cages before they were mated with virile males at different days in gestation. The rats in group 1 cage were 
commenced on the extract on the 7th day of gestation, while the animals on cage 8 were commenced on the 14th day 
of gestation. The remaining cages (2-7), were started on successive days of gestation.  Using the dating method, two 
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milliliters of the extract was administered orally from days 7, 8, 9, 10,11,12,13 and 14, which corresponded to cages 
1-8 of gestation respectively (Uche-Nwachi et al., 2004).
 Control groups made of 29 female rats were divided into groups of 4.Each group was mated with a viral 
male. This control group received distilled water orally in place of the extract. The aim was to get the same numbers 
of pups from the control and experimental groups for statistical analysis. Rats with no significant weight gain were 
sacrificed on day 22 to observe any resorption sites. After delivery the litter size and average pup weight from each 
group (control and experimental) was recorded. Malformed pups were also recorded. Pups were weighed daily and 
were individually marked when weaned. Pups were allowed to mature up to 45 days of age, when they were 
sacrificed via ether asphyxiation (Miettinen et al., 2002). Important organs which will determine the viability of the 
pups (brain, heart, lungs, liver, spleen) and organs from the same embryonic origin (kidney, ovaries, and testis), were 
harvested and observed for the presence of defects. The organs were weighed, and then fixed in Bouin’s fluid. 
Paraffin sections, (0.5 thick) were cut and stained with hematoxylin and eosin. A one-way ANOVA was used for 
the statistical analysis of the organ weight differences between experimental and control pups.
Results
Birth weights
Results showed that the mean birth weight of the experimental pups was 6.34g vs. 7.06g (p < 0.05), and that 
16 of the pups from the experimental animals (8.65%) were malformed as against 3 from the control (1.62%) 
{Table1}. These result also showed that while 5 pups from the experimental groups had multiple congenital 
malformations, none from the control group had such malformations (Table1).The result further showed that while 
the control rats had no resorption sites, the experimental rats had 9 resorption sites (Table 1, Figure 4a).  
Table 1: Mean litter size, body weight, resorption sites and congenital malformations in the pups from control and 
experimental animals
Control Experimental (MC)
Dams 29 24
Total number of pups 185 185
Males 83 83
Females 102 102
Mean litter size
Mean birth weight
6.4
7.06 g
7.7
6.34 g
Gross congenital malformation 3 16
% of congenital malformation 1.62 8.65
Males with malformations 1 10
Females with malformations 2 6
Multiple malformations 0 5
Resorption sites 0 9
Malformations
The result also showed that while only 1.62% of the control pups were malformed, 14.8% of the pups from 
day 7, 14.3% from day 8, 7.4% from day 9, 12.2% from day 11, 2.9% from day 12, 21.4% from day 13  had 
malformations. It also showed that there were no malformations on days 10 and 14 (Table 2). 
Mean organ weight
The result also showed that the mean weights of the kidney, the liver, the spleen, and the brain were 
significantly lower in the experimental pups, while the heart was significantly increased when compared with control
(p<0.05) {Table 3}.
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Figure 1a: Photograph of normal testes from control rats x40. Note the size and shapes of the testes (arrows).
Figure 1b: Photograph of undescended testes, (arrows) x40. Note the size and position of the testes inside the 
abdominal cavity.
Figure 1c: Photomicrograph (H&E), of normal testis from control rats x40.  Note the canalization of the semini-
ferous tubules (arrows).
Figure 1d: Photomicrograph (H&E), of the undescended testis from experimental rats.x40. Note the absence of 
canalization of the seminiferous tubules (arrows)
Histology 
Histological analysis also showed that the undescended testes had uncannalized seminiferous tubules (Fig
1d), and that the distended uterine horns had wide lumina (Figure 2c). Further analysis also showed that the atrophic 
ovary had no viable follicles (Fig 3b). It also showed multiple resorption sites in the experimental animals (Figure
4a).
Discussion
According to, Chan et al (1984), Leung and Yeung, (1987), Aguwa and Mittal. (1983), Grover and Yadav
(2004, Momordica charantia extracts have abortifacient properties. It has also been reported to reduce fertility in 
both males and females by Farnsworth and Waller (1982), and Basch et al. (2003). This present study showed that, 
there were 9 resorption sites in the experimental animals while the control had none (Table 1). The present study also 
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showed that 8.7 % of the experimental pups had malformations while only 1.6% of the control had malformations 
(Table 1).
Table 2: Distribution of malformations and resorption sites among the different days in gestation, the extracts was 
initiated
Day of 
gestation
Litter
Size
Normal
Pups
Pups
Affected
Malformation types Malformation
%
Resorption
Sites
Control 185 183 Female
Female
Male
Distended uterine 
horn and uterine 
atrophy
  Ovarian atrophy, 
Unilateral testicular 
agenesis
1.62 0
Day 7 27 23 Female
Female
Female
Male
Unilateral ovarian 
hypertrophy, Bilateral 
ovarian atrophy 
Bilateral ovarian 
atrophy, enlarged left 
lung and 
splenomegaly 
Cryptorchidism
14.8 0
Day 8 7 6 Female Uterine horn atrophy 14.3 9
Day 9 27 25 Male
Male
Bilateral testicular 
atrophy and 
hepatomegaly 
Hepatomegaly
7.4 0
Day 10 14 14 0 0 0
Day 11 41 36 Male
Male
Male
Male
Male
Cryptorchidism
Cryptorchidism and 
splenomegaly
Bilateral testicular 
atrophy, Hepatic 
atrophy and renal 
hypertrophy, Bilateral 
testicular atrophy and 
splenomegaly, 
Anencephaly and 
spinabifida
12.2 0
Day 12 34 33 Male Unilateral testicular 
hypertrophy
2.9 0
Day 13 14 11 Female
Female
Male
Distended uterine 
horns 
Distended uterine 
horns 
Hepatic atrophy
21.4 0
Day 14 22 22 0 0 0
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Table 3: Significant organ weight difference (P< 0.05)
Day Organ Mean organ 
weight of control 
(g)
Mean organ 
weight 
experimental (g)
P value
Significant at 
P<0.05
8 Brain 1.88 1.77 0.002
9 Heart 0.78 0.87 0.010
10 Heart 0.75 0.84 0.042
11 Liver 10.65 8.69 0.001
12 Liver 11.07 9.54 0.004
13 Brain 1.90 1.82 0.020
14 Kidney 1.89 1.59 0.003
14 Lungs 1.23 1.05 0.008
14 Liver 10.00 8.53 0.019
14 Spleen 0.82 0.66 0.038
Fig 2 a                                                                   Fig 2b
                                Fig 2b
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Figure 2a: Photograph of distended uterine horns from experimental rats (arrows) x40.
Figure 2b: Photograph of normal uterine horns from control rats (arrows) x40.
Figure 2c: Photomicrograph (H&E), of a cross section of distended uterine horn from experimental rat x40. Note the 
luminal size (arrow)
Figure 2d: Photomicrograph of  a cross section of a normal uterine horn from control rat, x40. Note the size of the 
lumen (arrow), when compared with Fig 2c above.
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Figure 3a: Photomicrograph (H&E), of a normal ovary from control rat, x40. Note the presence of corpora lutea (red 
arrows), and developing follicles (blue arrow).
Figure 3b: Photomicrograph (H&E), of the ovary from experimental rat x 40. Note the absence of corpus luteum 
and the absence of viable follicles.
Figure 4a: Photograph of resorption sites in the uterine horns of experimental rats (arrows) x 40.
Figure 4b: Photomicrograph (H&E), of early resorption from the uterine horn of experimental rat x40. Note the 
cavity of the horn filled with resorbed debris (arrow).
It was also demonstrated in this study that, the teratogenicity of the water extract of Momordica charantia
was dependent on the day of gestation it was administered. The present study also showed that reproductive organs 
were affected most in the malformed liters (Table 2), and that administering the extract from day 7, 11, and 13, 
showed the greatest number of malformations (Table 2). Furthermore, our result also showed that there was 
significant reduction in the weights of the brain, liver, kidney, lung, and spleen in the pups from the experimental 
animals, while there was a significant increase in the weight of the heart (Table 3). This implies that most organs 
from the pups of the experimental animals were affected in one way or another. The alterations in morphology and 
weight obviously may affect the respective functions of the affected organs. 
We therefore conclude that the water extract from the unripe fruit of Momordica charantia is teratogenic 
and that this was dependent on the period in gestation it was administered, and that the reproductive organs of the 
pups were most affected. We therefore advise that this preparation should be used with utmost caution during 
pregnancy in man.
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                                         Fig 4 a
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Figure 4c: Photomicrograph (H&E), of late resorption site from the uterine horn x40. Note the re-epithelization of 
the endometrium (arrow).
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